Pacific Edge (ASX:PEB, NZE:PEB) said the US District Court for the Middle District of Pennsylvania has ruled it lacks jurisdiction to review a Medicare coverage decision affecting the company's Cxbladder cancer test, according to a Thursday filing with the Australian bourse.
The Court determined it could not hear Pacific Edge's complaint against the Local Coverage Determination, the filing said.
In January, the company received confirmation that its flagship Cxbladder test would no longer be covered by US Medicare contractor Novitas.
If not challenged, the finalized decision would become effective, which means reimbursement of Pacific Edge's Cxbladder tests would end.
The ruling prevents the court from considering the scientific or medical merits of the company's claims.
Despite acknowledging the strength of the company's arguments, a Judge stated that the court was not empowered to intervene in the matter, the filing added.
The company said it has made its case for either retiring the LCD or delaying its implementation to officials at the US Centers for Medicare and Medicaid Services, the US Department of Health and Human Services, and the Office of the General Counsel.
The company's shares fell past 2% in New Zealand in recent Thursday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。